Diabetes

Real-world effectiveness data showed semaglutide reduced the risk of major kidney disease events by 26%.

Investigators also found that a change in brain functional network connectivity could also be associated with type 2 diabetes risk.

Patients who received pharmacist support reached their A1c goal 14 months sooner than those who did not receive the care.

For women in rural populations, access to education and care is limited, causing disparities in diabetes care.

Investigators find that the risk for new-onset diabetes is especially prominent for patients aged 20 to 29 years.

A modified DASH diet with lower sodium optimized for patients with type 2 diabetes reduced both systolic and diastolic blood pressure.

Hepatitis B and liver functions have been found to be independent risk factors for gestational diabetes and are found to have the highest prevalence of abnormalities.

Investigators found that longer durations of GLP-1 use were associated with increased risk of nAMD.

A significant number of patients remain unaware of their diabetes, signaling a need for better diagnostic efforts.

The associations and strengths of these links varied by the complication type, including diabetic nephropathy, neuropathy, and retinopathy.

Esaxerenone is a nonsteroidal mineralocorticoid receptor blocker that is being studied for its effectiveness for diabetes-associated mineralocorticoid receptor-related hypertension.

The results show promise, as vision typically improves the most during the first 4 weeks, but with lamivudine, vision continued to improve in the following 4 weeks.

Razanne Oueini, PharmD, MSc, CPHQ, discusses how rates of persistence to basal insulin were impacted after the IRA monthly cap.

Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.

A conversation with Razanne Oueini, PharmD, MSc, CPHQ, senior manager of Performance Measurement at PQA, at PQA 2025.

Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.

A conversation with Kaitlin Bates, PharmD, ARHOME Quality Manager at Arkansas Blue Cross and Blue Shield, at PQA 2025.

Glucagon-like peptide-1 receptor agonists have been associated with improvements in quality of life (QOL), restrained eating, and emotional eating behavior.

Abbott’s continuous glucose monitoring system is the first to show a reduction in cardiovascular complication severity.

Investigators also find that patients diagnosed with type 1 diabetes later in life do not have a better prognosis compared to those diagnosed earlier.

Investigators also found that nocturnal hypoglycemia is a strong predictor of daytime hypoglycemia.

Pharmacist-led interventions improve medication adherence compared with the usual care for patients with heart failure and type 2 diabetes.

Investigators find that unhealthy eating and inadequate or excessive sleeping duration could contribute to developing diabetic nephropathy.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.